Table 1.

Baseline characteristics of the clinical trial cohort

	INF	PLC	PLC taSJC inactive	PLC taSJC active	PLC taCRP inactive	PLC taCRP active	Total
Patients (n)	71	74	23	51	27	47	145
Age (years)	47.7±12.5	46.8±11.1	46.2±10.2	47.0±11.5	47.5±11.9	46.4±10.7	47.2±11.7
Female (%)	31.0	48.6	30.4	56.9	37.0	55.3	40.4
Disease duration (years)	8.6±6.7	8.5±8.3	10.2±10.4	7.8±7.2	9.9±9.5	7.7±7.6	8.6±7.6
SJC (0–66)	10.9±6.3	11.7±7.6	7.2±4.3	13.7±7.9	12.3±9.5	11.3±6.3	11.3±7.0
TJC (0–68)	20.0±13.3	19.3±11.8	14.6±13.4	21.4±10.5	20.8±12.8	18.4±11.2	19.6±12.5
CRP (mg/dL)	1.6±1.5	2.6±3.8	2.1±3.8	2.8±3.8	2.0±3.4	3.0±4.0	2.1±3.0
PGA (0–100 mm)	52.5±20.7	60.2±22.7	53.1±25.6	63.3±20.8	61.0±24.5	59.8±21.8	56.4±22.0
EGA (0–100 mm)	53.6±17.7	58.2±17.2	54.1±20.4	60.0±15.4	57.0±19.2	58.8±16.1	55.9±17.5
Pain (0–100 mm)	54.9±21.6	59.7±23.2	51.4±27.0	63.3±20.6	61.1±24.2	58.8±22.8	57.3±22.5
DAPSA	43.3±16.7	45.7±18.0	33.3±15.6	50.5±16.6	46.8±20.5	45.0±16.6	44.6±17.4
mTSS	20.3±30.7	47.6±92.9	65.7±113.7	39.5±81.8	40.7±72.8	51.6±103.2	34.3±70.9

Data are shown as mean±SD unless indicated otherwise.

CRP, C reactive protein; DAPSA, Disease Activity in Psoriatic Arthritis; EGA, evaluator global assessment; INF, infliximab; mTSS, total modified Sharp/van-der-Heijde Score; PGA, patient global assessment; PLC, placebo; SJC, swollen joint count; taCRP, time-averaged C reactive protein; taSJC, time-averaged swollen joint count; TJC, tender joint count.